358 related articles for article (PubMed ID: 19372041)
1. Early clinical trial concept for boron neutron capture therapy: a critical assessment of the EORTC trial 11001.
Wittig A; Collette L; Moss R; Sauerwein WA
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S59-62. PubMed ID: 19372041
[TBL] [Abstract][Full Text] [Related]
2. Suitability of boron carriers for BNCT: accumulation of boron in malignant and normal liver cells after treatment with BPA, BSH and BA.
Chou FI; Chung HP; Liu HM; Chi CW; Lui WY
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S105-8. PubMed ID: 19375330
[TBL] [Abstract][Full Text] [Related]
3. Delivery of (10)boron to oral squamous cell carcinoma using boronophenylalanine and borocaptate sodium for boron neutron capture therapy.
Obayashi S; Kato I; Ono K; Masunaga S; Suzuki M; Nagata K; Sakurai Y; Yura Y
Oral Oncol; 2004 May; 40(5):474-82. PubMed ID: 15006618
[TBL] [Abstract][Full Text] [Related]
4. Boron neutron capture therapy (BNCT) inhibits tumor development from precancerous tissue: an experimental study that supports a potential new application of BNCT.
Monti Hughes A; Heber EM; Pozzi E; Nigg DW; Calzetta O; Blaumann H; Longhino J; Nievas SI; Aromando RF; Itoiz ME; Trivillin VA; Schwint AE
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S313-7. PubMed ID: 19376711
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution of BPA and BSH after single, repeated and simultaneous administrations for neutron-capture therapy of cancer.
Ichikawa H; Taniguchi E; Fujimoto T; Fukumori Y
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S111-4. PubMed ID: 19376721
[TBL] [Abstract][Full Text] [Related]
6. Optimization of boron neutron capture therapy for the treatment of undifferentiated thyroid cancer.
Dagrosa MA; Thomasz L; Longhino J; Perona M; Calzetta O; Blaumann H; Rebagliati RJ; Cabrini R; Kahl S; Juvenal GJ; Pisarev MA
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1059-66. PubMed ID: 17967301
[TBL] [Abstract][Full Text] [Related]
7. Selective uptake of p-boronophenylalanine by osteosarcoma cells for boron neutron capture therapy.
Ferrari C; Zonta C; Cansolino L; Clerici AM; Gaspari A; Altieri S; Bortolussi S; Stella S; Bruschi P; Dionigi P; Zonta A
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S341-4. PubMed ID: 19394838
[TBL] [Abstract][Full Text] [Related]
8. Disposition of TF-PEG-Liposome-BSH in tumor-bearing mice.
Ito Y; Kimura Y; Shimahara T; Ariyoshi Y; Shimahara M; Miyatake S; Kawabata S; Kasaoka S; Ono K
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S109-10. PubMed ID: 19395268
[TBL] [Abstract][Full Text] [Related]
9. [Neutron capturing irradiation: principle, current results and perspectives].
Pignol JP; Chauvel P
Bull Cancer Radiother; 1995; 82(3):283-97. PubMed ID: 8554878
[TBL] [Abstract][Full Text] [Related]
10. Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT).
Maruyama K; Ishida O; Kasaoka S; Takizawa T; Utoguchi N; Shinohara A; Chiba M; Kobayashi H; Eriguchi M; Yanagie H
J Control Release; 2004 Aug; 98(2):195-207. PubMed ID: 15262412
[TBL] [Abstract][Full Text] [Related]
11. Boron biodistribution study in colorectal liver metastases patients in Argentina.
Cardoso J; Nievas S; Pereira M; Schwint A; Trivillin V; Pozzi E; Heber E; Monti Hughes A; Sanchez P; Bumaschny E; Itoiz M; Liberman S
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S76-9. PubMed ID: 19375931
[TBL] [Abstract][Full Text] [Related]
12. EORTC trial 11001: distribution of two 10B-compounds in patients with squamous cell carcinoma of head and neck, a translational research/phase 1 trial.
Wittig A; Collette L; Appelman K; Bührmann S; Jäckel MC; Jöckel KH; Schmid KW; Ortmann U; Moss R; Sauerwein WAG
J Cell Mol Med; 2009 Aug; 13(8B):1653-1665. PubMed ID: 19602035
[TBL] [Abstract][Full Text] [Related]
13. Boron neutron capture therapy at the crossroads: challenges and opportunities.
Barth RF
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S3-6. PubMed ID: 19467879
[TBL] [Abstract][Full Text] [Related]
14. Applicability of the 2-nitroimidazole-sodium borocaptate-10B conjugate, TX-2060, as a 10B-carrier in boron neutron capture therapy.
Masunaga S; Nagasawa H; Hiraoka M; Sakurai Y; Uto Y; Hori H; Nagata K; Suzuki M; Maruhashi A; Kinashi Y; Ono K
Anticancer Res; 2004; 24(5A):2975-83. PubMed ID: 15517904
[TBL] [Abstract][Full Text] [Related]
15. Maximum therapeutic depth in thermal neutron capture therapy.
Allen BJ
Strahlenther Onkol; 1993 Jan; 169(1):34-41. PubMed ID: 8434338
[TBL] [Abstract][Full Text] [Related]
16. [Boron neutron capture therapy applied to undifferentiated thyroid carcinoma].
Pisarev MA; Dagrosa MA; Thomasz L; Juvenal G
Medicina (B Aires); 2006; 66(6):569-73. PubMed ID: 17240633
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution of boron compounds in an animal model of human undifferentiated thyroid cancer for boron neutron capture therapy.
Dagrosa MA; Viaggi M; Rebagliati RJ; Batistoni D; Kahl SB; Juvenal GJ; Pisarev MA
Mol Pharm; 2005; 2(2):151-6. PubMed ID: 15804189
[TBL] [Abstract][Full Text] [Related]
18. Analysis of 10B antitumoral compounds by means of flow-injection into ESI-MS/MS.
Basilico F; Sauerwein W; Pozzi F; Wittig A; Moss R; Mauri PL
J Mass Spectrom; 2005 Dec; 40(12):1546-9. PubMed ID: 16320299
[TBL] [Abstract][Full Text] [Related]
19. Combination of the vascular targeting agent ZD6126 with boron neutron capture therapy.
Masunaga S; Sakurai Y; Suzuki M; Nagata K; Maruhashi A; Kinash Y; Ono K
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):920-7. PubMed ID: 15465210
[TBL] [Abstract][Full Text] [Related]
20. Survival benefit from boron neutron capture therapy for the newly diagnosed glioblastoma patients.
Kawabata S; Miyatake S; Nonoguchi N; Hiramatsu R; Iida K; Miyata S; Yokoyama K; Doi A; Kuroda Y; Kuroiwa T; Michiue H; Kumada H; Kirihata M; Imahori Y; Maruhashi A; Sakurai Y; Suzuki M; Masunaga S; Ono K
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S15-8. PubMed ID: 19398348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
